Percutaneous Imaging-guided Cryoablation of Endometriosis Scars of the Anterior Abdominal Wall.
Abdominal wall endometriosis
Endometriosis
Minimaly invasive treatment
Percutaneous cryoablation
Journal
Journal of minimally invasive gynecology
ISSN: 1553-4669
Titre abrégé: J Minim Invasive Gynecol
Pays: United States
ID NLM: 101235322
Informations de publication
Date de publication:
Nov 2023
Nov 2023
Historique:
received:
16
05
2023
revised:
27
06
2023
accepted:
27
06
2023
medline:
7
11
2023
pubmed:
9
7
2023
entrez:
8
7
2023
Statut:
ppublish
Résumé
To evaluate the safety and clinical efficacy of percutaneous imaging-guided cryoablation for the management of anterior abdominal wall endometriosis. Patients with abdominal wall endometriosis underwent percutaneous imaging-guided cryoablation and had a 6-month follow-up. Data dealing with patients' and anterior abdominal wall endometriosis (AAWE) characteristics, cryoablation, and clinical and radiologic outcomes were retrospectively collected and analyzed. Twenty-nine consecutive patients underwent cryoablation from June 2020 to September 2022. Interventions were performed under US/computed tomography (CT) guidance or magnetic resonance imaging (MRI) guidance. Cryoprobes were directly inserted into the AAWE, and cryoablation was performed with a single 5 to 10 minute freezing cycle, which was stopped when the iceball expanded 3 to 5 mm beyond AAWE borders as assessed on intra-procedural cross-sectional imaging. Fifteen patients (15/29; 51.7%) had prior endometriosis, 28 (28/29; 95.5%) had previous cesarian section, and 22 (22/29; 75.9%) referred association between symptoms and menses. Cryoablation was performed under local (16/29; 55.2%) or general anesthesia (13/29; 44.8%) and mainly in an out-patient basis (18/20; 62%). There was only one (1/29; 3.5%) minor procedure-related complication. Complete symptom relief was recorded in 62.1% (18/29) and 72.4% (21/29) patients at 1 and 6 months, respectively. In the whole population, pain significantly dropped at 6 months compared to the baseline (1.1 ± 2.3; range 0-8 vs 7.1 ± 1.9; range 3-10; p <.05). Eight (8/29; 27.6%) patients presented residual symptoms at 6 months, and 4 (4/29; 13.8%) had an MRI-confirmed residual/recurring disease. Contrast-enhanced MRI obtained for the first 14 (14/29; 48.3%) patients of the series, all without signs of residual/recurring disease, demonstrated a significantly smaller ablation area compared to the baseline volume of the AAWE (1.0 cm Percutaneous imaging-guided cryoablation of AAWE is safe and clinically effective in achieving pain relief.
Identifiants
pubmed: 37422051
pii: S1553-4650(23)00276-5
doi: 10.1016/j.jmig.2023.06.018
pii:
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
890-896Informations de copyright
Copyright © 2023 AAGL. Published by Elsevier Inc. All rights reserved.